

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A04/2017 OS

DESPATCHED ON 28TH MARCH 2017

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A24; B8, B39; Cw7, Cw12; DR4, DR16; DQ5, DQ8

				Summary of Results												
				PBL				T-Cells				B-Cells				
				13	13	10	12	37	38	38	38	36	34	37	28	
				13	0	1	0	35	0	1	0	36	2	35	17	
				0	13	9	12	2	38	37	38	0	32	2	11	
				2	2	5	3	1	0	0	0	3	5	2	11	
				100.0%	0.0%	10.0%	0.0%	94.6%	0.0%	2.6%	0.0%	100.0%	5.9%	94.6%	60.7%	
				0.0%	100.0%	90.0%	100.0%	5.4%	100.0%	97.4%	100.0%	0.0%	94.1%	5.4%	39.3%	
				Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Not Assessed	
HLA Antibody Specificity (Defined By CDC)				A10 B16 DQ1	A32 B44 DR7	DQ3	DR3 DR5 DR6	A10 B16 DQ1	A32 B44 DR7	DQ3	DR3 DR5 DR6	A10 B16 DQ1	A32 B44 DR7	DQ3	DR3 DR5 DR6	
				Without DTT				Without DTT				Without DTT				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
101		YES	YES	NT	NT	NT	NT	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	Results not conclusive
112	YES							Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	Dealted delivery. Low B-cell viability
114		YES	YES					Positive	Negative	Negative	Negative	Equivocal	Negative	Equivocal	Equivocal	
116		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
119	YES			Positive	Negative	Equivocal	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
120		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
128	YES			Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Equivocal	
133		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
139	YES			Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
143		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
145		YES	YES	Equivocal	Negative	Negative	Negative	Equivocal	Negative	Negative	Negative	Equivocal	Negative	Positive	Negative	
147	YES			Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
154		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
157		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
159		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
162		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
163		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
169		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	NT	Positive	Positive	Low number of cells
181		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Equivocal	
186		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	Positive	Positive	Positive	Positive	
189	YES			Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Equivocal	
190		YES	YES	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Positive	NT	
193	YES			Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Equivocal	
194		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Equivocal	Cells arrives clustered in the sample
195		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
197		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
204		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Equivocal	Positive	Equivocal	Very low B-cell viability
206		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Equivocal	
209	YES			Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
216	YES			Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Positive	
223		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Positive	
227		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	NT	Technical failure
229	YES															No results returned
232	YES			NT	NT	NT	NT									Samples held in customs
235	YES			Positive	Negative	NT	Negative	Positive	Negative	Negative	Negative	Positive	Equivocal	Positive	Positive	Serum 2 - Anti DQ3 MFI 6000
238	YES	YES	YES	Positive	Negative	Equivocal	Equivocal	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
239	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
245	YES	YES	YES	Positive	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
252	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
259	YES															No results returned
260		YES	YES					Positive	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
268		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
284		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
292		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
293		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
294		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
297		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
321		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
351		YES	YES	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Serum 3 was hemolyzed

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A04/2017 OS

DESPATCHED ON 28TH MARCH 2017

Lab No.	PBL without DTT				T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
101					6	1	1	1	8	1	6	1			
112	NT	NT	NT	NT									80		
114					8	1	1	1	8	1	8	8			
116					6-8	1	1	1	0	0	0	0		95	50
119	8	1	2	1									90		
120					8	1	1	1	8	1	8	1		100	100
128	6	1	1	1									95		
133					8	-	-	-	8	-	8	22c - Neg 37c - 4	95	95	95
139	8	1	1	1	8	1	1	1	8	1	8	6	80	80	80
143					8	1	1	1					90		
145					Equivocal	-	-	-	Equivocal	-	8	-	100	100	100
147	8	1	1	1	8	1	1	1	8	1	8	4	100	100	100
154					8	1	1	1	8	1	2	2	99		
157					4	1	1	1	8	1	8	4		85	50
159					8	1	1	1	8	1	8	1		100	85
162					8	-	-	-	8	-	8	6		100	100
163					8	1	1	1	8	1	8	4		80	70
169					8	1	1	1	8	NT	8	8		99	99
181					8	1	1	1	8	1	8	4		95	95
186					8	0	4	0	8	4	8	8		99	99
189	6	1	1	1	1	1	1	1	6	1	1	1	95		
190					1	1	1	1	100	1	100	20		99	90
193	4	1	1	1	6	1	1	1	8	1	8	NT	99	99	97
194					-	-	-	-	-	-	-	Equivocal			
195					6	1	1	1	6	1	6	4		85	85
197					-	-	-	-	-	-	-	Weak		80	80
204					8	1	1	1	8	6	8	8		90	50
206					8	1	1	1	8	1	8	4		90	80
209	8	1	1	1					8	1	8	8		90	85
216	8	1	1	1									95		
223					8	2	1	1	8	8	8	8		95	95
227					8	-	-	-	8	-	8	NT		98	98
229															
232					NT	NT	NT	NT							
235	8	1	NT	1									85		
238	8	1	2	2	8	1	1	1	8	2	8	6	90	90	70
239	++++	-	-	-	++++	-	-	-	++++	-	++++	-	90	90	90
245	8	1	4	1	8	1	1	1	8	1	8	6	100	100	100
252	6	2	2	2					6-8	2-4	6	4	85		65
259															
260					++++	-	-	-	NT	NT	NT	NT		90	10
268					8	1	1	1	8	1	1	1		90	20
284					8	1	1	1	8	1	8	6		98	95
292					6	-	-	-	8	-	8	-		85	35
293					4	0	0	0	8	0	8	0		70	70
294					8	0	0	0	8	0	8	4		100	98
297					8	1	1	1	8	2	8	8	100	100	100
321					4	1	1	1	8	1	8	1		97	97
351					2	1	1	1	8	1	2	1	90		

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A04/2017 OS

DESPATCHED ON 28TH MARCH 2017

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A24; B8, B39; Cw7, Cw12; DR4, DR16; DQ5, DQ8

				Summary of Results												
				PBL				T-Cells				B-Cells				
				12	12	9	11	33	34	34	34	33	30	34	25	
				12	0	1	0	30	0	0	0	33	1	32	15	
				0	12	8	11	3	34	34	34	0	29	2	10	
				1	1	3	2	2	1	1	1	2	5	1	8	
				100.0%	0.0%	11.1%	0.0%	90.9%	0.0%	0.0%	0.0%	100.0%	3.3%	94.1%	60.0%	
				0.0%	100.0%	88.9%	100.0%	9.1%	100.0%	100.0%	100.0%	0.0%	96.7%	5.9%	40.0%	
Consensus				Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Not Assessed	
HLA Antibody Specificity (Defined By CDC)				A10 B16 DQ1	A32 B44 DR7	DQ3	DR3 DR5 DR6	A10 B16 DQ1	A32 B44 DR7	DQ3	DR3 DR5 DR6	A10 B16 DQ1	A32 B44 DR7	DQ3	DR3 DR5 DR6	
				With DTT				With DTT				With DTT				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
101		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
112	YES	YES	YES	NT	NT	NT	NT									Results not conclusive
114		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
116		YES	YES					Positive	Negative	Negative	Negative	Equivocal	Equivocal	Equivocal	Equivocal	Dealted delivery. Low B-cell viability
119	YES			Positive	Negative	Equivocal	Negative									
120		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
133		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Equivocal	
139	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
143		YES						Positive	Negative	Negative	Negative					
147	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative					
157		YES	YES					NT	NT	NT	NT	Positive	Negative	Positive	Positive	
159		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
162		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
163		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
169		YES	YES					Positive	Negative	Negative	Negative	Positive	NT	Positive	Positive	Low number of cells
181		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Positive	Equivocal	
186		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
189	YES			Positive	Negative	Negative	Negative									
190		YES	YES					Negative	Negative	Negative	Negative	NT	NT	Positive	NT	Too much mortality on B-cells
193	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	NT	
194		YES	YES					Equivocal	Negative	Negative	Negative	Positive	Negative	Positive	Equivocal	
195		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Positive	Equivocal	Cells arrives clustered in the sample
197		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
204		YES	YES					Positive	Negative	Negative	Negative	Positive	Equivocal	Positive	Equivocal	Very low B-cell viability
206		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Positive	Equivocal	
209	YES		YES	Positive	Negative	Negative	Negative					Positive	Negative	Positive	Negative	
216	YES			Positive	Negative	Negative	Negative									
227		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Positive	NT	Technical failure
229	YES															No results returned
235	YES															Serum 3 not tested because it is haemolysis
238	YES	YES	YES	Positive	Negative	NT	Negative	Positive	Negative	Negative	Negative	Positive	Equivocal	Positive	Positive	Serum 2 - Anti DQ3 MFI 6000
245	YES	YES	YES	Positive	Negative	Equivocal	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
252	YES		YES	Positive	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
260		YES	YES									NT	NT	NT	NT	Low B-cell viability
262	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Positive	
268		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
284		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
292		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
293		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
294		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
297		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
321		YES	YES					Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
351		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Heat inactivation instead of with DTT. Serum 2 was hemolyzed

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A04/2017 OS

DESPATCHED ON 28TH MARCH 2017

Lab No.	PBL with DTT				T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
101					6	1	1	1	8	1	8	1			
112	NT	NT	NT	NT									80		
114					8	1	1	1	8	1	8	8			
116					6-8	1	1	1	0	0	0	0		95	50
119	4	1	2	1									90		
120					4	1	1	1	8	1	8	1		100	100
133					-	-	-	-	8	-	8	4	95	95	95
139	8	1	1	1	8	1	1	1	8	1	8	6	80	80	80
143					8	1	1	1					90		
147	8	1	1	1	8	1	1	1	8	1	8	4	100	100	100
157					NT	NT	NT	NT	8	1	8	8		85	50
159					8	1	1	1	8	1	8	6		100	85
162					8	-	-	-	8	-	8	6		100	100
163					8	1	1	1	8	1	8	4		80	70
169					8	1	1	1	8	NT	8	8		99	99
181					8	1	1	1	8	2	8	4		95	95
186					8	0	0	0	8	4	8	6		99	99
189	6	1	1	1	1	1	1	1	6	1	1	1	95		
190					1	1	1	1	NT	NT	100	NT		99	90
193	6	1	1	1	6	1	1	1	8	1	8	0	99	99	97
194					Equivocal	-	-	-	-	-	-	Equivocal			
195					6	1	1	1	6	1	6	4		85	85
197					-	-	-	-	-	-	-	-		80	80
204					6	1	1	1	8	6	8	8		90	50
206					8	1	1	1	8	1	8	4		90	80
209	4	1	1	1					8	1	8	1		90	85
216	8	1	1	1									95		
227					8	-	-	-	8	-	8	NT		98	98
229															
235	8	1	NT	1									85		
238	8	1	2	2	8	1	1	1	8	2	8	6		90	70
245	8	1	4	1	8	1	1	1	8	1	8	6	100	100	100
252	6	2	2	2					6-8	2-4	6	4		85	65
260					++	-	-	-	NT	NT	NT	NT		90	10
262	6	1	1	1	4	1	1	1	8	6	8	8	100	100	100
268					8	1	1	1	8	1	1	1		90	20
284					8	1	1	1	8	1	8	8		98	95
292					4	-	-	-	8	-	6	-		85	35
293					8	0	0	0	8	0	8	0		70	70
294					6	0	0	0	8	0	8	4		100	98
297					8	1	1	1	8	2	8	8	100	100	100
321					4	1	1	1	8	1	8	1		97	97
351					1	1	1	1	8	1	2	1		90	